Phrontline Biopharma has secured a $60 million Pre-A+ financing round, a significant milestone that strengthens its position as one of the most advanced developers of bispecific and dual-payload antibody-drug conjugates. The raise underscores strong investor conviction in the company’s platform and its potential to shift the global ADC landscape. With this new capital, Phrontline is expanding its clinical programs, deepening global operations, and accelerating strategic partnerships that reinforce its technology and commercial reach.
Advancing a Next-Generation ADC Platform
Founded in 2022, Phrontline has rapidly built a fully integrated ADC development engine spanning antibody discovery, linker–payload engineering, site-specific conjugation, and functional testing. This platform supports both bispecific and dual-payload ADCs, designed to address resistance, tumor heterogeneity, and limited durability often seen in single-target approaches. By combining two mechanisms of action in one molecule, the company aims to produce more potent and more resilient therapeutics for hard-to-treat solid tumors.
Strategic Use of the $60 Million Raise
The financing will support multiple priorities across clinical and preclinical programs, including ongoing first-in-human trials for TJ101, an EGFR and B7-H3 bispecific ADC. Funds will also expand global clinical operations as the company prepares for simultaneous development across the United States, China, and additional geographies. Beyond pipeline progression, the raise empowers Phrontline to scale manufacturing and strengthen collaborations that enhance development speed and international access.
Investor Confidence in Phrontline’s Vision
The round was led by Lapam Investment with participation from Samsung Venture Investment Corporation, Guofang Innovation, Hankang Venture Capital, Songqing Capital, Jifeng Ventures, and Sino Biopharmaceutical Limited. Existing shareholders including Decheng Capital, Medfine Health Fund, and C&D Emerging Investment also increased their commitments, signaling deep confidence in the company’s trajectory. Their renewed support reflects Phrontline’s strong scientific foundations, clear execution strategy, and sizable potential to become a central player in next-generation oncology therapeutics.
Strengthening Global Reach Through Partnerships
Recent collaborations illustrate Phrontline’s focus on global expansion and complementary alliances. The company signed a strategic partnership with Samsung Bioepis to co-develop two next-generation bispecific and dual-payload ADC candidates, integrating Phrontline’s technology with Samsung’s development and manufacturing capabilities. It also entered an exclusive licensing agreement with Sino Biopharmaceutical Limited for TJ101 in Mainland China and the Hong Kong SAR, positioning its lead asset for accelerated regional development.
Leadership Perspective on Scientific Momentum
Tony Chen, Founder and Chief Executive Officer, emphasized that the company’s strategy is rooted in biology and translational science rather than incremental development. He noted that dual-target synergy and complementary payload mechanisms are showing early validation through preclinical and emerging clinical data. Chen expressed gratitude to both new and returning investors, emphasizing that the financing supports Phrontline’s mission to bring truly innovative ADC therapies to patients worldwide.
Phrontline’s $60 million Pre-A+ financing round represents more than capital infusion, it provides the foundation the company needs to scale its next-generation ADC platform globally. With strong investor backing, expanding clinical programs, and strategic partnerships already underway, Phrontline is positioned to accelerate development of therapies aimed at overcoming some of oncology’s most persistent challenges. The momentum behind this raise suggests the company is stepping into a pivotal phase as it works to redefine precision cancer treatment.